BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34567939)

  • 1. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy.
    Sejima T; Masago T; Yoshida M; Nishi T; Kawabata Y; Tajima Y; Yumioka T; Honda M; Takenaka A
    Int Cancer Conf J; 2021 Oct; 10(4):285-289. PubMed ID: 34567939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
    George G; Schmidt L; Tolat P; Riese M; Kilari D
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
    Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
    Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcomatoid renal cell carcinoma with an inferior vena cava tumor thrombus that was completely resected by robot-assisted laparoscopic radical nephrectomy after neoadjuvant therapy nivolumab plus ipilimumab: a case report.
    Tsuchiyama A; Ohba K; Nakanishi H; Yasuda T; Nakamura Y; Kurohama H; Mitsunari K; Matsuo T; Mochizuki Y; Imamura R
    Int Cancer Conf J; 2024 Jan; 13(1):6-10. PubMed ID: 38187173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature.
    Hino C; Nishino K; Pham B; Jeon WJ; Nguyen M; Cao H
    Front Immunol; 2022; 13():993622. PubMed ID: 36052087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma.
    Shirotake S; Miyama YU; Baba Y; Tajima H; Okada Y; Nakazawa K; Usami Y; Yasuda M; Igarashi D; Kaneko GO; Kanao K; Oyama M; Nishimoto K
    Anticancer Res; 2022 May; 42(5):2727-2735. PubMed ID: 35489743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab.
    Hayashida M; Miura Y; Noda T; Yamanaka T; Tanaka N; Yasuoka S; Oka S; Sakaguchi K; Kinowaki K; Urakami S
    IJU Case Rep; 2022 Jul; 5(4):268-272. PubMed ID: 35795114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
    Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V
    Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report.
    Furubayashi N; Taguchi K; Negishi T; Miura A; Sato Y; Miyoshi M; Nakamura M
    In Vivo; 2022; 36(1):510-521. PubMed ID: 34972756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.
    Shaw LK; Wiele AJ; Sircar K; Wood CG; Msaouel P
    Cancer Treat Res Commun; 2021; 27():100349. PubMed ID: 33725559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma.
    Kobari Y; Yoshida K; Iizuka J; Kondo T; Ishida H; Tanabe K; Takagi T
    In Vivo; 2021; 35(6):3585-3589. PubMed ID: 34697199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma.
    Takahashi M; Takishita M; Yamazato Y; Kakinoki H; Udo K; Tobu S; Noguchi M
    CEN Case Rep; 2023 May; 12(2):237-241. PubMed ID: 36402939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
    Tachibana H; Ishiyama Y; Yoshino M; Yamashita K; Toki D; Kondo T
    In Vivo; 2021; 35(3):1743-1747. PubMed ID: 33910858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete pathologic response after laparoscopic hepatectomy following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high colon cancer liver metastasis consisting of poorly differentiated adenocarcinoma with squamous differentiation: A case report.
    Kato M; Sawayama H; Komohara Y; Hisano Y; Nakamura H; Ohuchi M; Ogawa K; Miyamoto Y; Yoshida N; Baba H
    Clin J Gastroenterol; 2024 Feb; 17(1):57-64. PubMed ID: 37874527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A Case of Metastatic Renal Cell Carcinoma with Arthritis and Colitis Due to Immune-Related Adverse Events During Ipilimumab-Nivolumab Combination Therapy].
    Toyoshima M; Ikarashi D; Tsuboi H; Moriwaka M; Tamada S; Matsuura T; Maekawa S; Kato R; Kanehira M; Takata R; Sugimura J; Obara W
    Hinyokika Kiyo; 2023 Aug; 69(8):227-232. PubMed ID: 37667600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab.
    Tomioka M; Nakane K; Ozawa K; Iinuma K; Suzui N; Miyazaki T; Koie T
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1356. PubMed ID: 33656804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma.
    Kikuchi H; Osawa T; Matsumoto R; Abe T; Maruyama S; Harabayashi T; Miyata H; Kashiwagi A; Ikeshiro S; Sazawa A; Fukui R; Morita K; Takeuchi I; Hori K; Yamashita N; Minami K; Mochizuki T; Murai S; Shinohara N
    Urol Oncol; 2022 Jan; 40(1):13.e19-13.e27. PubMed ID: 34716079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
    Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI
    Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.